Signal Transducer and Activator of Transcription 3 (STAT3) Degradation by Proteasome Controls a Developmental Switch in Neurotrophin Dependence*

Background: As neonatal hippocampal neurons mature, STAT3 levels increase via an unknown mechanism, which makes neurons neurotrophin-independent. Results: STAT3 protein levels are low in neonates because of calcineurin-dependent proteasomal degradation of STAT3. Conclusion: Calcineurin-dependent STAT3 degradation regulates the survival of neonatal neurons. Significance: Proteasomal degradation controls the developmental switch of neurotrophin dependence. Neonatal brains develop through a program that eliminates about half of the neurons. During this period, neurons depend on neurotrophins for their survival. Recently, we reported that, at the conclusion of the naturally occurring death period, neurons become neurotrophin-independent and, further, that this developmental switch is achieved by the emergence of a second survival pathway mediated by signal transducer and activator of transcription 3 (STAT3). Here I show that calcineurin plays a key role in controlling the developmental switch in mouse hippocampal neurons. Calcineurin promotes the degradation of STAT3 via the ubiquitin-proteasome pathway. Inhibition of calcineurin acutely increases total levels of STAT3 as well as its activated forms, resulting in decreased levels of the tumor suppressor p53 and its proapoptotic target, Bax. In vivo and in vitro, calcineurin regulates levels of STAT3 and neurotrophin dependence. TMF/ARA 160 (TATA element modulatory factor/androgen receptor co-activator 160), the key mediator of STAT3 ubiquitination, is required for calcineurin-dependent STAT3 degradation. Thus, these results show that the ubiquitin-proteasome pathway controls the critical developmental switch of neurotrophin dependence in the newborn hippocampus.

Protein levels can be regulated not only by transcription and translation but also by the rate of degradation. The proteasome is a large protease complex ubiquitously found in all types of cells, including neurons (1), where proteins tagged with ubiquitin are destined for destruction (2). The proteasomal degradation of misfolded proteins (3) appears to be especially critical in neurons, and its failure is thought to underlie a number of neurodegenerative diseases (4). However, besides its role in quality control, the ubiquitin-proteasome pathway also regulates important cellular functions, such as cell division (5) and stress response (6). Many signaling pathways, including necrosis factor B (7), Wnt (8), and hypoxia-inducible factor (9), utilize the inhibition of proteasome-dependent degradation as a type of signal transduction. In developing neurons, a precise balance between ubiquitination and deubiquitination is required for the formation of proper neural circuitry (10).
In early postnatal life, the central nervous system (CNS) goes through a specific developmental stage during which approximately half of its neurons are eliminated (11). In rodent hippocampus, this wave of developmental death occurs during the first 10 postnatal days (12,13). During this period, neurons depend on neurotrophin signaling for their survival (14). Recently, we reported that, after this period of vulnerability, neurons became resistant to the lack of neurotrophin-signaling and that this developmental switch was achieved by the emergence of a second survival pathway mediated by signal transducer and activator of transcription 3 (STAT3) (15). STAT3 mediates cytokine signaling (16) and plays a critical role in embryonic brain development (17). We found that Ser(P)-727 STAT3 is required for the resistance to the lack of neurotrophin signaling in hippocampal neurons and that the developmental switch from the neonatal to adult survival pathway was achieved not simply by changing the phosphorylation state of but rather by changing the total protein levels of STAT3 (15). However, the mechanism responsible for increasing STAT3 protein during development is unknown.
Calcineurin is a calcium/calmodulin-dependent Ser/Thr phosphatase (18). Although its roles in T-cell activation and cytokine production are well known (19), calcineurin was originally purified from brain tissue (20) and has been implicated in several aspects of neuronal development (21)(22)(23) and brain function (24). Here I show that the developmental switch in neurotrophin dependence in postnatal hippocampal neurons is regulated by calcineurin. In early postnatal hippocampal neurons, calcineurin effectively promotes the proteasomal degradation of STAT3, whose survival signal later allows mature neurons to achieve resistance against neurotrophin deprivation. Thus, this work shows that the ubiquitin-proteasome system controls a critical developmental step in newborn hippocampus.
with the blocking solution. Samples were incubated for 2 h with antibodies.
For the in vivo injection analyses, pups were perfused with 4% PFA 2 days after the injection. Consecutive coronal slices 50 m thick were made by a Leica VT100S vibrating microtome (Leica, Allendale, NJ) and were immunostained with a neuronal marker, NeuN, and an apoptotic marker, c-cas3. Slices were compared with respect to distance from the injection site. The analysis was done blind with respect to the content of the injections.
Cell Quantification-Fluorescent images were taken with a Zeiss confocal microscope (LSM-510) equipped with a ϫ10, ϫ25, or ϫ40 lens. Z-Stacked images from eight sections (1-m intervals) were used for the analyses. Images were analyzed with ImageJ. For cell survival assays, images were taken from five fields: one from the center of the coverslip and two vertically and two horizontally 400 -3000 m from the center. Because the densities of neurons were higher near the rim of coverslips than in other regions, we avoided sampling the coverslips' edges. The mean number of neurons of five fields was then calculated. Each coverslip was defined as an individual culture. Numbers given represent means Ϯ S.E. For immunofluorescence intensity analyses, ROI Manager in ImageJ was used to select soma areas of Z-stacked images, and mean intensities were measured. The TATA element modulatory factor (TMF)/ androgen receptor co-activator 160 (ARA 160) distribution assay followed the Golgi distribution assay (26); the position where the apical dendrite emerges was defined as ϭ 0°, and quadrants 1-4 were defined as 315°-44°, 45°-134°, 135°-224°, and 225°-315°. The background was subtracted in each image. All analyses were done blind.
Transfection-Transfection was performed using Lipofectamine 2000 (Invitrogen). Cells were transfected with 1.6 g/ml pEGFPC1 vector (Clontech, Mountain View, CA), 8 g/ml constitutively activated calcineurin (⌬CaN)/pSRa vector (gift from Dr. U. Siebenlist, NAID/National Institutes of Health), 30 pM mouse ARA 160 siRNA or mouse TMF/ARA 160 siRNA (Santa Cruz Biotechnology, Inc.), and/or wild-type STAT3 internal ribosome entry site enhanced green fluorescent protein/pMX in OPTI-MEM (Invitrogen) for 15 min, and then the medium was replaced with NeuroBasal medium. Cells were cultured in NeuroBasal medium (osmolarity adjusted to 290 osM with sucrose) before and after the transfection in order to maximize the transfection efficiency.
Immunoprecipitation-Cultures were incubated for 15 min with 40 l of lysis buffer per well (150 mM NaCl, 1% Nonidet P-40, and 50 mM Tris-HCl (pH 8.0) containing a protease inhibitor mixture (Roche Applied Science) and then collected and centrifuged at 12,000 ϫ g for 10 min. Supernatants were preabsorbed with 10% (v/v) protein A-conjugated Sepharose beads (Amersham Biosciences) for 1 h and then centrifuged at 3000 ϫ g for 3 min. The supernatant was incubated with 1% (v/v) STAT3 antibody for 2 h followed by 10% (v/v) protein A-conjugated Sepharose beads for 1 h. The beads were then washed with the lysis buffer twice. Proteins were eluted with 10ϫ (v/v) SDS sample buffer. The procedure was done at 4°C.
Chromatin Immunoprecipitation (ChIP)-Chromatin immunoprecipitation assays were performed as described by Ballas et al. (27). Cultures were fixed with 4% paraformaldehyde, permeabilized in 0.5% Triton X-100, and collected with 40 ml/well of cell lysis buffer (5 mM Hepes, pH 8, 85 mM KCl, and 0.5% Triton X-100) containing 1 mM phenylmethylsulfonyl fluoride (PMSF) and then centrifuged at 3000 rpm for 2 min at 4°C, and the pellet was resuspended in cell lysis buffer with PMSF and centrifuged at 3000 rpm for 2 min at 4°C two times. The pellet was then resuspended in nuclear lysis buffer (50 mM Tris-HCl, pH 8, 10 mM EDTA, 1% SDS) with 1 mM PMSF and was sonicated to yield 100 -1000 bp of DNA on ice and was centrifuged at 12,000 rpm for 15 min at 4°C. The nuclear lysate was preabsorbed with recombinant protein G-agarose (Invitrogen) preincubated with 200 g/ml yeast tRNA and 200 g/ml salmon sperm (Invitrogen) for 1 h at 4°C. The chromatin suspension was diluted with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8, 167 mM NaCl) and then immunoprecipitated with 5 g/ml monoclonal mouse anti-STAT3 overnight at 4°C. The chromatin suspension was incubated with recombinant protein G-agarose pretreated with 3% BSA and yeast tRNA and salmon sperm for 4 h at 4°C. Agarose beads were washed with a series of solutions as follows at room temperature: ChIP dilution buffer, dialysis buffer (2 mM EDTA, 50 mM Tris-HCl, pH 8, 0.2% Sarkosyl), TSE-500 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8, 500 mM NaCl), LiCl detergent (100 mM Tris, pH 8, 500 mM LiCl, 1% Triton X-100, 1% deoxycholic acid), and TE (10 mM Tris-HCl, pH 8, 1 mM EDTA). To change the solution, the beads were centrifuged at 3000 rpm for 1 min, and the supernatant was aspirated. The samples were eluted from the beads with 300 l of elution buffer (50 mM NaHCO 3 , 1% SDS). Samples were incubated overnight at 65°C to reverse PFA cross-links, following the addition of 20 l of 5 M NaCl. DNA was then purified from the eluted samples using the Qiagen PCR purification kit (Qiagen, Valencia CA). PCR was performed to analyze the STAT3 binding site in the mouse p53 promoter using the following DNA primers: 5Ј-GGGCCCGTFTTGGTTCATCC-3Ј and 5Ј-CCGCGAGACTCCTGGCACAA-3Ј. Conditions for PCRs were 30 cycles of 94°C (30 s), 60°C (30 s), and 72°C (1 min). The PCR products were separated in a 1.5% agarose gel.
Calcineurin Assay-The enzymatic activity of calcineurin was determined using a colorimetric calcineurin assay kit (Calbiochem). Cultures and brain tissue were homogenized with lysis buffer with protein inhibitor mixture as described above. Phosphatase assays were performed following the manual provided by the vendor. The activity was measured with 150 M RII phosphopeptide as a substrate, incubated at 30°C for 30 min. Absorbance at 620 nm was measured using a Beckman spectrophotometer DU600 (Beckman, Brea, CA). The endogenous phosphate concentrations were separately measured in the assay buffer without calmodulin, and the values were subtracted. Protein concentration was determined using a Pierce BCA protein assay kit (Thermo Scientific, Rockford, IL). For each reaction, 5 l of sample lysate, which contained ϳ90 g of total protein, were used.
In Vivo Injection-In vivo injection to CA1 was described previously (28). Briefly, Sprague-Dawley rat pups (P2) of either sex were anesthetized by hypothermia (in ice for 5 min) prior to the surgery. The anesthetized animal was placed on ice in a stereotaxic instrument. The stereotaxic coordinates from the bregma are as follows: AP ϩ1.5, ML Ϯ1.8, VD Ϫ1.8 mm. 0.3 l of reagents were delivered at a rate of 0.1 l/min using a using a Hamilton needle and syringe attached to a microsyringe pump controller (World Precision Instruments (Sarasota, FL)). Concentrations of reagents were as follows: FK506, 30 M; anti-TrkB antibody, 0.5 mg/ml. PBS was used as a control. The incision was closed using a polyglycolic acid suture (CP Medical, Portland, OR). Animals were allowed to recover at 37°C for 1-2 h.
Statistical Analyses-Statistical significance between two groups was determined with a two-tailed paired Student's t test. For multiple groups, statistical comparisons were made by ANOVA followed by individual group tests with the Bonferroni correction made for multiple comparisons.

STAT3 Increases during Postnatal Development via Post-
transcriptional Regulation-To examine if STAT3 transcription is regulated during the first 10 days postnatal, mRNA levels in tissue samples were analyzed by RT-PCR. Despite the notable increase in protein level detected by Western blot analysis during this period, mRNA levels remained unchanged (Fig. 1A). The in vitro system exhibited the same phenomenon, an increase in protein level while mRNA level stayed constant (Fig.  1B). Immunostaining showed that MAP2 ϩ cells increased STAT3 between 7 days in vitro (DIV7) and DIV14 (Fig. 1C).
These results indicate that the increase in neuronal STAT3 during development was caused by post-transcriptional regulation.
Calcineurin Is Involved in Regulating the STAT3-p53-Bax Pathway-What regulates the STAT3 protein level in developing neurons? Inhibition of calcineurin by FK506 acutely up-regulated STAT3 protein levels (Fig. 2, A and B); within 15 min of adding FK506 to young neurons (DIV7), STAT3 protein dramatically increased (5.0 Ϯ 1.3-fold, n ϭ 4, p ϭ 0.025, Student's t test), as did its phosphorylated forms (Ser(P)-STAT3 and Tyr(P)-STAT3). A lesser but notable increase also occurred in more mature neurons (DIV14) that are not dependent on neurotrophin TrkB signaling for survival (15). Phosphorylation of STAT3 induces it to dimerize and translocate to the nucleus, where it binds to its target DNA (29). Immunostaining for STAT3 revealed an accumulation of STAT3 in nuclei (Fig. 2B), consistent with the increase in active forms of STAT3. STAT3 is known to negatively regulate the tumor suppressor gene, p53 (30). To check if inhibition of calcineurin affects the binding of STAT3 to the p53 promoter, chromatin immunoprecipitation (ChIP) analysis was performed. A brief (15-min) exposure to FK506 resulted in an increase in STAT3 binding to the p53 promoter (Fig. 2C). After a 2-h incubation with FK506, both the mRNA level and the protein level of p53 decreased (assessed by RT-PCR and Western blot with immunostaining, respectively, Fig. 3, A and B). Bax, a proapoptotic target of p53 (31), was also decreased by FK506 (Fig. 3A). To test if STAT3 is involved in the regulation of p53 levels, STAT3 was knocked down by siRNA. Following a 2-h treatment with FK506, neurons cotransfected with siRNA for STAT3 showed strong staining for p53, whereas neurons transfected only with GFP expression vector showed much weaker staining for p53 (Fig. 3C). These data suggest that calcineurin down-regulates p53 via STAT3. Significant reductions in levels of p53 and Bax in hippocampus were observed during neonatal development in vivo (Fig. 3A), suggesting that these changes may be developmentally relevant.
Calcineurin Regulates Neurotrophin Dependence through STAT3-Next, the effect of calcineurin on developmental neuronal death was examined. We reported previously that neurons during the developmental death period depend on brainderived neurotrophic factor (BDNF) for survival (14). Consistent with our previous observation, the number of neurons transfected with GFP-expressing vector decreased during  the death period (DIV5-DIV8), and the number of transfected neurons further decreased when treated with the functionblocking anti-TrkB antibody (Fig. 4A). Treatment with FK506, the inhibitor of calcineurin, blocked the spontaneous neuronal death, and the number of surviving neurons did not decrease following co-incubation with the anti-TrkB antibody (Fig. 4A), suggesting that neurons became neurotrophin-independent, and the survival effect of FK506 is not achieved by inhibition of TrkB signal down-regulation. As we previously reported, these young neurons during the death period contain very low levels of STAT3 (15). Concomitantly, STAT3 knockdown by siRNA did not increase the amount of death; however, treatment of these neurons with FK506 did not block their death (Fig. 4A), suggesting that the survival effect of FK506 is STAT3-dependent.
Calcineurin becomes calcium-independent and constitutively activated when the C terminus of its catalytic subunit is deleted (32). When neurons were co-transfected with a vector expressing ⌬CaN, the spontaneous death of neurons increased. However, when calcineurin activity was blocked by FK506 in these neurons, the death was completely attenuated (Fig. 4A). Co-transfection with a STAT3-expressing vector also blocked the neuronal death. These results suggest that calcineurin controls survival of neurons through regulation of STAT3.
To examine whether calcineurin activity is developmentally regulated, the phosphatase activity levels of immature (DIV7) and older (DIV14) neurons were compared. A significant decrease in calcineurin activity was observed between primary cultures maintained at DIV7 and DIV14 (Fig. 4B). A similar result was obtained when the phosphatase activity was measured using acutely prepared hippocampal tissue (Fig. 4B). Whether calcineurin is responsible for TrkB independence in the mature neurons (DIV14) was checked next. As reported previously (15), treatment with anti-TrkB antibody did not cause death in the GPF-expressing mature neurons (Fig. 4C). Neurons co-transfected with a vector expressing ⌬CaN only showed a tendency to reduced numbers presumably due to higher levels of endogenous BNDF, but a significant number of neurons died following the addition of the function-blocking anti-TrkB antibody, suggesting that the neurons became TrkBdependent. The effect of overexpressing ⌬CaN was completely reversed by adding FK506 or overexpressing STAT3 (Fig. 4C), suggesting that STAT3 is also responsible for calcineurin-induced TrkB-dependence in the mature neurons. Taken together, these results suggest that calcineurin regulates TrkB dependence in immature and more mature neurons through STAT3.    JULY 12, 2013 • VOLUME 288 • NUMBER 28

JOURNAL OF BIOLOGICAL CHEMISTRY 20155
Calcineurin Induces STAT3 Degradation via the Ubiquitin-Proteasome Pathway-Next, the post-transcriptional mechanism that allows calcineurin to regulate STAT3 protein level was explored. Preincubation with anisomycin, an inhibitor of translation, did not block the effect of FK506 on STAT3 protein levels (Fig. 5A), suggesting that calcineurin regulates the stability of STAT3 protein. Moreover, when neurons were incubated in MG-132, an inhibitor of the proteasome, STAT3 protein increased to a level similar to that in neurons incubated in FK506 (Fig. 5A). To further investigate the role of calineurin in proteasome-dependent STAT3 degradation, immunoprecipitation analyses were performed (Fig. 5B). Immunoprecipitation using the antibody against STAT3 gave a single band at around 90 kDa, and no bands were observed in the sample treated without the antibody in the immunoblotting with STAT3 antibody, showing that the antibody specifically immunoprecipitated STAT3 (Fig. 5B). The sample treated with the proteasome inhibitor, MG-132, showed a high smeared signal in addition to an increased level of 90-kDa species (Fig. 5B). Treatment with FK506 increased the level of 90-kDa species without the higher molecular species (Fig. 5B). When these samples were analyzed by ubiquitin immunoblot, a reduction in the 90 kDa band was observed in the FK506-treated sample as compared with the control, whereas the MG-132-treated sample showed a smeared signal both higher and lower than 90 kDa (Fig. 5B). These results suggest that calcineurin controls the ubiquitination of STAT3.
A previous study showed that ubiquitinated Tyr(P)-STAT3 was not detected (33), suggesting that only the inactive form of STAT3 is subjected to degradation. Therefore, whether calcineurin changed the phosphorylation state of STAT3 was tested next. In the presence of the proteasome inhibitor MG-132, neither Ser(P)-STAT3 nor Tyr(P)-STAT3 was increased by the addition of FK506, whereas the general Tyr phosphatase inhibitor, orthovanadate, dramatically increased Tyr(P)-STAT3 without affecting Ser(P)-STAT3 levels (Fig. 5C), suggesting that calcineurin does not dephosphorylate Tyr(P)-STAT3 in these neurons. Then the effect of Tyr phosphorylation on STAT3 stability using orthovanadate was further examined. Exposure to orthovanadate caused only a small increase in the total STAT3 as compared with the increase induced by MG-132 (Fig. 5D). Together, these results suggest that calcineurin affects the stability of STAT3 mainly by promoting proteasome-dependent degradation and that the stabilization effect by dephosphorylating STAT3 is limited.
For a protein to become ubiquitinated, it has to be directed to the E3 ubiquitin ligase complex (34,35). Human immunodeficiency virus 1 TMF (36)/ARA 160 (37) has been reported to interact with elongin C in the E3 ligase complex through the BC-box motif and to mediate degradation of STAT3 (38). Therefore, whether TMF/ARA 160 is involved in the regulation of STAT3 levels in hippocampal neurons was checked next. Immunostaining for TMF/ARA 160 confirmed its expression in immature neurons. Applying siRNA for TMF/ARA 160 effectively knocked down this expression and resulted in a large increase in STAT3 (Fig. 6A). Whether or not a similar mechanism operates in more mature neurons was tested next. When older neurons (DIV14) were transfected with ⌬CaN-expressing vector, STAT3 levels were significantly reduced (Fig. 6B, p Ͻ 0.001). However, when neurons were co-transfected with siRNA for TMF/ARA 160, STAT3 levels were not affected (Fig.  6B). These results suggest that TMF/ARA 160 is involved in regulating STAT3 levels.
To examine if TMF/ARA160 is sensitive to calcineurin activity, the distribution of TMF/ARA 160 was analyzed. Immunostaining for TMF/ARA 160 in control neurons showed scattered puncta throughout the soma area, whereas in FK506treated neurons, puncta were accumulated on one side of the perinuclear region (Fig. 7A). Quadrant distribution analyses showed that TMF/ARA 160 in the cell body was evenly distributed in the control condition, whereas FK506-treated neurons showed higher TMF/ARA 160 signals on the side of apical den-  JULY 12, 2013 • VOLUME 288 • NUMBER 28 drites (Fig. 7A). These results suggest that the distribution of TMF/ARA 160 is sensitive to calcineurin activity.

STAT3 Degradation Controls a Developmental Switch
To further investigate how calcineurin affects STAT3 degradation, the effects of FK506 and MG-132 on other proteins that are degraded by the ubiquitin-proteasome system were compared. A tyrosine kinase, Fer, is known to interact with TMF/ ARA 160 (39). Treatment with FK506 increased levels of Fer protein to levels similar to that induced by MG-132 treatment (Fig. 7B). In contrast, p35, the activator for cyclin-dependent kinase (Cdk5), and hypoxia-inducible factor 1␣ (HIF1␣), whose degradation is regulated by a tumor suppressor protein, VHL (40), were sensitive to MG-132 but not to FK506 (Fig. 7B). In fact, no effect on the total ubiquitin levels was observed when neurons were treated with FK506 (Fig. 7B). These results suggest that the effect of calcineurin is more TMF/ARA 160-specific than regulating proteasome activity itself. Also, total ubiquitin levels were found not to change during postnatal development (data not shown). Therefore, it is unlikely that the developmental increase in STAT3 protein levels is caused by changes in proteasome activity.

Calcineurin Regulates Survival of Newborn Hippocampal
Neurons in Vivo-Next, whether or not the regulation of STAT3 by calcineurin controls the survival of neonatal hippocampal neurons in vivo was examined. When FK506 was injected into CA1 of P2 hippocampus, STAT3 protein levels increased without a concomitant increase in mRNA levels (Fig. 8A), consistent with the   results obtained in vitro. Apoptotic hippocampal neurons in these pups (P4) were analyzed by immunostaining for c-cas3 and NeuN (Fig. 8B). c-cas3 ϩ neurons showed fragmented nuclei revealed by DAPI staining (Fig. 8B), a feature characteristic of apoptotic cells. Inhibiting calcineurin decreased the numbers of apoptotic neurons in the entire hippocampus, including CA3 and stratum oriens (SO), as well as CA1 (Fig.  8C). Injecting anti-TrkB antibody, on the other hand, increased the numbers of apoptotic neurons in these regions of hippocampus (Fig. 8C). Consistent with experiments performed in vitro, when FK506 and anti-TrkB antibody were co-injected into the pups, the numbers of apoptotic neurons were significantly lower than those injected with vehicle, indicating that treated neurons could survive independent of TrkB signaling (Fig. 8C). These experiments confirm that calcineurin indeed regulates the survival of newborn hippocampal neurons in vivo.

DISCUSSION
Calcineurin Promotes Proteasome-dependent Degradation of STAT3 in Neonatal Hippocampal Neurons-As we reported previously, as neurons pass through the developmental death period, they lose their early dependence on neurotrophin when a new survival pathway mediated by STAT3 signaling arises to take its place (15). Results presented here, summarized in Fig. 9, show that this developmental change is caused by a decrease in the calcineurin activity that promotes degradation of STAT3 through the ubiquitin-proteasome pathway. These results establish that 1) calcineurin inhibitor rapidly increases the amount of STAT3 protein in the presence of anisomycin; 2) proteasome inhibitor increases STAT3 with a similar rate and magnitude as the calcineurin inhibitor; and 3) immunoprecipitation of STAT3 reveals the accumulation of ubiquitinated STAT3 by a proteasome inhibitor, an effect that is attenuated by the calcineurin inhibitor. Further, TMF/ARA 160, the protein responsible for translocating STAT3 to the proteasome (38), was present in hippocampal neurons, and knocking down its gene by siRNA effectively up-regulated STAT3 protein levels. Overexpressing ⌬CaN caused a striking decrease in STAT3 levels, an effect that was attenuated by co-expressing TMF/ ARA 160 siRNA, suggesting that calcineurin affects TMF/ARA 160-mediated degradation. Thus, this study assigns an important new role for calcineurin in regulating the ubiquitin-proteasome dependent STAT3 degradation.
Overall levels of ubiquitinated protein were unchanged during the postnatal period. FK506 did not affect total ubiquitinated protein levels either. The observation that FK506 affected the distribution of TMF/ARA 160 suggests that the association of the STAT3-E3 ligase complex is calcineurin-dependent. Moreover, FK506 increased the levels of another protein, Fer, that also interacts with TMF/ARA 160, but other proteins whose ubiquitination is mediated by different systems were not affected. These results suggest that calcineurin affects TMF/ ARA 160 specifically, rather than indirectly by regulating proteasome activity. TMF/ARA 160 was originally identified as a DNA-binding protein (36,37); however, it was later shown that TMF/ARA 160 mainly localizes in the Golgi apparatus (41). A scattered distribution of TMF/ARA 160 is also observed in myoblast cells when they are starved of serum (38), and it is thought that dispersion of TMF/ARA 160 enhances accessibility to STAT3 and thus increases the degradation of STAT3. The precise mechanism by which calcineurin causes dispersion of TMF/ARA 160 remains to be determined. Understanding the trafficking of TMF/ARA 160 may provide some clues.
Calcineurin Regulates Neurotrophin Dependence by Promoting STAT3 Degradation-The calcineurin inhibitor increased both Ser(P)-and Tyr(P)-STAT3 species in amounts proportional to the total amount of STAT3 protein, and, as a result, STAT3 accumulated in neuronal nuclei and bound to the promoter of p53. Calcineurin inhibitor decreased the levels of p53 and its target gene product, Bax, in a STAT3-dependent manner. Consistent with this decrease in the proapoptotic protein Bax, calcineurin inhibitor promoted the survival of immature neurons. This survival effect of calcineurin inhibitor is not achieved by blocking the negative regulation of Trk signaling because these neurons become resistant to anti-TrkB treatment. In a complementary finding, overexpressing constitutively activated calcineurin caused mature neurons to re-express a regressive sensitivity to the blockade of neurotrophin In an immature neuron, calcineurin stimulates degradation of STAT3 by the ubiquitin-proteasome pathway. TMF/ARA 160 is required for STAT3 degradation. In a mature neuron, diminished calcineurin activity results in stabilization of STAT3, which effectively represses a tumor suppressor, p53. The STAT3 survival signaling allows mature neurons to achieve resistance against neurotrophin deprivation. Ub, ubiquitin.
signaling; mature neurons otherwise do not require neurotrophin to survive. Gain-and-loss of STAT3 function experiments suggested that the effect of calcineurin on survival depends on STAT3. In vivo and in vitro, immature neurons contained low levels of STAT3, high levels of p53 and Bax, and high calcineurin activity as compared with more mature neurons after the death period.
The phosphorylation state of the proteins plays a key role in the induction of proteasome-dependent degradation (7)(8)(9). Although calcineurin is a Ser phosphatase (42), calcineurin has been reported to promote dephosphorylation of Tyr(P)-STAT3 (43), and the Tyr(P)-705 STAT3 species has not been detected among ubiquitinated proteins (33) in non-neuronal cells. This raises the possibility that the survival effect of calcineurin inhibitor might be mediated by the inhibition of dephosphorylation of Tyr(P)-STAT3 in young neurons. However, whereas orthovanadate, the general Tyr phosphatase inhibitor, effectively up-regulated Tyr(P)-STAT3, the calcineurin inhibitor did not change levels of Tyr(P)-STAT3 in the presence of the proteasome inhibitor. Moreover, FK506 increased STAT3 protein levels in a similar manner as the proteasome inhibitor, whereas orthovanadate only slightly increased STAT3 in young neurons. These results establish that, in these neurons, any contribution of phosphorylation state to the stability of STAT3 is minimal; rather, the calcineurin inhibitor promotes survival by reducing STAT3 degradation by proteasome.
Calcineurin responds to neuroactivity and mediates synaptic plasticity (44 -46). Therefore, the survival effect of FK506 may be achieved through neuroactivity. In fact, as we demonstrated previously (14), neuronal activity plays a critical role in the survival of neonatal neurons. However, it is unlikely because knockdown of STAT3 completely attenuated the survival effect of FK506. Calcineurin is known to influence cell survival by regulating transcription factors (47)(48)(49). However, the results reported here reveal an important new function of calcineurin. Calineurin also mediates developmental change in synaptic properties (50). Therefore, inhibiting calcineurin in these young neurons may lead to a delay of normal synaptic maturation.
Calcineurin in newborn hippocampus showed much greater enzymatic activity than that in older hippocampus that had already gone through the developmental death period. The mechanism for regulating calcineurin has not yet been determined. When young neurons (DIV7) were briefly (2 min) depolarized with 50 mM KCl in the presence of anisomycin, STAT3 protein levels significantly decreased in 2 h (52.7 Ϯ 19.1% of the control, n ϭ 4, p ϭ 0.012), suggesting that neuroactivity induced degradation of STAT3. However, blocking spontaneous activity induced death instead of mimicking the survival effect of calcineurin (14). Moreover, elevation of excitability did not decrease the total levels of STAT3 (15). These results suggest that spontaneous activity may not be the major pathway to the activation of calcineurin. Calcineurin is regulated by anchoring proteins or regulators (51)(52)(53). Intriguingly, the spatial and temporal expression patterns of the regulators of calcineurin are dramatically reconfigured during the postnatal period (54). Although calcineurin activity declines during the postnatal period, it nonetheless remains important for normal hippocampal function in the adult (55), suggesting that its activity needs to be well titrated. In fact, both dysregulated calcineurin activity (56) and a marked decrease in STAT3 (57) have been observed in the aged brain. Therefore, the connections between calcineurin activity and neuronal survival signaling reported here are likely to contribute to novel approaches to treat neurodegenerative diseases.